Important information for pharmaceutical companies regarding electronic pharmacovigilance reporting

15. April 2021 – The number of reports of adverse drug reactions (ADR) has risen steadily in recent years. This trend has increasingly been observed both in Switzerland and in other countries in recent years. The increase is primarily attributable to a rise in the number of reports received from the pharmaceutical industry. To ensure that reports are processed promptly and possible risks are identified swiftly in future too, Swissmedic continually adapts its working methods and conducts them on a paperless basis as far as possible. As a result, from 1 July 2021 only electronic reports will be accepted.

For more information, see here.